Challenges of minimal residual disease monitoring in patients with leukemia during chimeric antigen receptor modified T cell immunotherapy
10.3760/cma.j.issn.1009-9158.2018.03.001
- VernacularTitle:嵌合抗原受体修饰T细胞治疗时代白血病患者微小残留病监测面临的挑战
- Author:
Gusheng TANG
1
;
Tao WANG
;
Jianmin YANG
Author Information
1. 海军军医大学(第二军医大学)附属长海医院血液科
- Keywords:
Chimeric antigen receptor modified T cell;
Leukemia;
Minimal residual disease
- From:
Chinese Journal of Laboratory Medicine
2018;41(3):175-179
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor modified T cell(CAR-T)immunotherapy has achieved remarkable success in the treatment of hematological malignancies,especially for relapsed/refractory acute B lymphocytic leukemia(B-ALL)leukemia patients,most of whom could obtain complete remissions or partial remissions.However,clinical studies also found a as high as 50%total recurrence rate of these patients,in which more than 20% patients relapsed with tumor cells not expressing the primary CAR-T-targeted CD molecules.Increased relapses with negative targeted-molecules or even lost primary abnormal tumor gene, suggesting that immune escape and even clonal evolution events increased rapidly under the high -precision CAR-T immunotherapy pressure.Monitoring of minimal residual disease(MRD)is important to assess the efficacy and find recurrence trends early in a timely manner to guide further clinical intervention.The new features of disease recurrence after CAR-T treatment have put forward higher requirements for traditional and emerging MRD detection methods so as to ensure their effectiveness in the CAR-T treatment era.
